DKP Critical Insights Report
Cancer Drug Access: Clinical Drivers and Influencers
The oncology environment changes almost daily, and the integration of clinical perspectives are central to many of the value-based initiatives. Whether understanding the trends in pathway decisions and other unique approaches to managing oncology drugs, or the influence of clinical compendia, these clinical drivers are important.
DK Pierce is known for its deep-dive knowledge of drivers and influencers for the delivery of cancer care. This message highlights two DK Pierce year-end 2017 updated reports under its DKP Critical Insights® market intelligence services, all designed to inform your market access strategies.
These oncology-specific updated 2017 reports include the ability to:
- Test assumptions for, and create a successful compendia submission strategy
- Assess and develop value messages for your product(s)
- Learn how payers and providers are evolving in their development and application of oncology pathways, oncology benefit management and other initiatives
- Identify geographic trending in clinical decision making
- Understand the important influence of clinical drug compendia for oncology drug decisions, and specific compendium nuances and submission requirements
Contact Amy Schroeder, RPh, Senior Consultant, to learn more about pricing and content for these and other DK Pierce reports. Don’t forget that DK Pierce also publishes Payers’ User of Compendia for Off-Label Indications in Oncology, outlining commercial payers’ use of clinical compendia for oncology drug decision making.
If purchasing two or more of the DK Pierce Critical Insights® reports, DKP staff will be available for a one-hour strategic planning session (at no charge) to help you understand the top line implications of each report, specific to your market/indication.
To learn more, contact us at info@dkpierce.net, visit our website at www.dkpierce.net, or call us at 317-873-0303.
Amy Schroeder, RPh, Senior Consultant
Contact her at amy.schroeder@dkpierce.net or (317) 873-0303 ext. 212.
